New registry aims to unlock secrets of rare sarcoma
NCT ID NCT05910307
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is building a large collection of medical data and biological samples from 1,000 people with synovial sarcoma, a rare cancer. Researchers will use this information for future genetic studies to better understand the disease and improve treatments. Participants provide access to medical records, leftover tumor tissue, and may give blood or saliva samples, plus complete questionnaires over up to 10 years.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this registry could help researchers better understand synovial sarcoma and develop new treatments.
- What could go wrong
- This is an observational registry, not a treatment trial. It collects information for future studies, so there is no direct benefit to participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 1,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2023
- Expected to finish
-
Jun 2033
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Males and females of any age with a reported diagnoses of synovial sarcoma.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Males or females of any age 2. Reported diagnosis of synovial sarcoma 3. Informed consent from subject (aged ≥18 years) or parent/guardian Exclusion Criteria: 1. Individuals with sarcomas that do not fit the definition of those considered for this registry 2. Individuals who are unwilling to participate 3. Individuals who are unwilling or unable to provide written consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Synovial sarcoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Children's Hospital of Philadelphia
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a genetic marker guide future cancer therapies in taiwan?
- Experimental drug tazemetostat offered to patients with rare, aggressive tumors
- New pill may keep soft tissue sarcoma in check after chemo
- Glow-in-the-Dark dye could help surgeons find hidden lung cancer in teens
- New cell therapy targets Hard-to-Treat cancers in first human trial
- Engineered immune cells take aim at multiple cancers in early trial